(Q61932645)

English

Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy (English)

0 references

0 references

0 references

United States of America

0 references

start time

September 2003

0 references

number of participants

42

0 references

research intervention

valproic acid

0 references

clinical trial phase

phase I clinical trial

0 references

research site

University of Utah Health Care

0 references

research subject recruitment status

completed

0 references

minimum age

2 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT00374075

0 references

(Q61932645)

Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)